New miR-124 activators have been reported in a recent Nanjing Synnocare Pharmaceutical Technology Co. Ltd. patent as potentially useful for the treatment of Alzheimer type dementia, Parkinson’s disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, cancer and viral infections.
IRCCS San Raffaele, Universita Degli Studi Di Perugia and Universita Vita-Salute San Raffaele have jointly developed new oxysterols receptor LXR-α (NR1H3; LXRA) and/or LXR-β (NR1H2; LXRB) antagonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
A Scandiedge Therapeutics AB patent details compounds targeting pyruvate kinase PKLR reported to be useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma.
The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer.
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis due to rapid growth, early metastases and acquired drug resistance, making it difficult to manage.
Cancer immunotherapy based on programmed death 1 ligand 1 (PD-L1) has made huge steps toward overcoming cancer, but many patients still experience poor response to anti-PD-L1 therapy or do not have a durable response.
Orsobio Inc. has closed an oversubscribed $67 million series B financing, the proceeds of which will be used to accelerate development of its mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders.
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
Researchers from Chroma Medicine Inc. presented preclinical data for the novel PCSK9-targeted epigenetic editor (PCSK9-EE) being developed as cardiovascular therapy for the reduction of low-density lipoprotein cholesterol.
Integrated Nanotherapeutics Inc. has received an award from Breakthrough T1D (formerly Juvenile Diabetes Research Foundation Ltd. [JDRF]) to advance the company’s technology to induce immune tolerance in type 1 diabetes.
RSS
